Physician profile
Stephen L Roth
NPI 1982645040
$7,696.26
in general payments reported to CMS, 2019-2025
18 companies · $91.58 in 2025
The $91.58 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,061 · 2020: $676 · 2021: $1,789 · 2022: $1,363 · 2023: $455 · 2024: $260 · 2025: $91.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,141.04 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $821.36 | 2019-2022 | |
| Amarin Pharma, INC. | $709.72 | 2019-2020 | |
| Novo Nordisk INC | $654.54 | 2019-2025 | Ozempic |
| Glaxosmithkline, LLC. | $639.61 | 2019-2023 | |
| Amgen INC. | $490.93 | 2019-2021 | |
| Abbvie INC. | $486.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $430.27 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $380.50 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $365.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.21 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $302.24 | 2021-2024 | Farxiga |
| Pfizer INC. | $232.64 | 2019-2020 | |
| Lilly USA, LLC | $224.82 | 2023-2024 | Jardiance, Mounjaro |
| Genentech USA, INC. | $150.00 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $125.03 | 2020 | |
| Ironwood Pharmaceuticals, INC | $125.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $94.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.